Thomas Samaille

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Journal: JCO oncology practice

Published: March 26, 2026

Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: a cohort study.

Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: a cohort study.

Journal: ESMO gastrointestinal oncology

Published: March 23, 2026

Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors.

Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors.

Journal: Clinical colorectal cancer

Published: January 06, 2026

Impact of germline MMR gene variants on immune checkpoint inhibitors response in patients with MSI-H/dMMR digestive cancers: a retrospective cohort analysis.

Impact of germline MMR gene variants on immune checkpoint inhibitors response in patients with MSI-H/dMMR digestive cancers: a retrospective cohort analysis.

Journal: Hereditary cancer in clinical practice

Published: December 11, 2025

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Journal: Clinical colorectal cancer

Published: November 03, 2025

Pancreatic acinar cell carcinoma: Clinical and theranostic characteristics

Pancreatic acinar cell carcinoma: Clinical and theranostic characteristics

Journal: Bulletin du cancer

Published: October 13, 2025

Therapeutic de-escalation strategies in the use of anti-PD-1 and anti-PD-L1: Dose, frequency, and duration

Therapeutic de-escalation strategies in the use of anti-PD-1 and anti-PD-L1: Dose, frequency, and duration

Journal: Bulletin du cancer

Published: October 05, 2025

Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management.

Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 16, 2025

Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making.

Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making.

Journal: International journal of cancer

Published: June 25, 2025

Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study.

Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study.

Journal: ESMO open

Published: January 06, 2025

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy.

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy.

Journal: ESMO gastrointestinal oncology

Published: July 16, 2024

Claudine 18.2: A new therapeutic target in digestive cancers

Claudine 18.2: A new therapeutic target in digestive cancers

Journal: Bulletin du cancer

Published: May 14, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026